Skip to main content
Clinical Trials/NCT00758056
NCT00758056
Unknown
Not Applicable

A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Endometrial Cancer in East Anglia, Oxford Trent and West Midlands

Cancer Research UK1 site in 1 country2,000 target enrollmentFebruary 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endometrial Cancer
Sponsor
Cancer Research UK
Enrollment
2000
Locations
1
Primary Endpoint
Acquisition of epidemiological information and biological material
Last Updated
12 years ago

Overview

Brief Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with endometrial cancer.

Detailed Description

OBJECTIVES: * To obtain epidemiological information and biological material on a population-based series of endometrial cancer cases. * To define the proportion of endometrial cancer incidence attributable to mutations in known predisposing genes such as MSH2 and MLH1. * To determine the risk associated with these predisposing mutations by examining the cancer risk in relatives of patients who are shown to be carriers. * To examine the effect of nongenetic risk factors in mutation carriers. * To determine the pathological and clinical characteristics of endometrial cancers occurring in mutation carriers as compared with that in noncarriers. * To establish whether mutations at other loci may predispose to endometrial cancer by comparing the frequency of alterations in endometrial cancer patients with the corresponding frequency in cancer-free controls identified through the European Prospective Investigation of Cancer (EPIC) study. OUTLINE: This is a multicenter study. Patients complete an epidemiological questionnaire. The questionnaire will request identifying information about the patient's first-degree relatives. Blood samples are collected from patients. DNA is extracted from these blood samples and from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL as well as from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes. In addition to the endometrial cancer patients recruited for this study, patients with breast, ovarian, prostate, colorectal, bladder, kidney, pancreatic, brain and esophageal cancer, malignant melanoma, and lymphoma cancer are recruited in the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-PROSTATE, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-CANCER.

Registry
clinicaltrials.gov
Start Date
February 2008
End Date
TBD
Last Updated
12 years ago
Study Type
Observational
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Acquisition of epidemiological information and biological material

The prevalence of endometrial cancer attributable to mutations in known predisposing genes such as MSH2 and MLH1

Determination of risk associated with these predisposing mutations by examining the cancer risk in relatives of patients who are shown to be carriers

Examination of the effect of nongenetic risk factors in mutation carriers

The pathological and clinical characteristics of endometrial cancers occurring in mutation carriers as compared with that in noncarriers

Exploration of mutations at other loci that may predispose to endometrial cancer

Study Sites (1)

Loading locations...

Similar Trials